ABSTRACT
AIM:To analyze circulating miR-141 in the serum as a non-invasive biomarker in the patients with prostate cancer ( PCa) and benign prostate hyperplasia ( BPH) , and healthy individuals.METHODS: A total of 75 pa-tients with PCa, 52 with BPH and 40 healthy individuals were enrolled into this study.Total RNA was isolated from the se-rum samples and the circulating levels of miR-141 were determined using quantitative real-time polymerase chain reaction. RESULTS:The serum levels of miR-141 were significantly higher in the patients with PCa compared to the patients with BPH and the healthy controls (P0.05).The serum miR-141 level was also found to be related to Gleason score, clinical stage and bone me-tastasis status of the patients with PCa (P0.05 for all comparisons).CONCLUSION: Circulating miR-141 could serve as a non-invasive biomarker for prostate cancer diagnosis, staging and prognosis prediction.
ABSTRACT
A DNA fragment encoding recombinant human interleukin 11 (hrIL-11) was obtained by PCR from previously constructed pET24a-hrIL-11 plasmid. Then pET21a-hrIL-11 expression vector was constructed routinely and transformed into BL-21(DE3). By the induction of Isopropyl-1-thio-beta-D-galactoside (IPTG), hrIL-11 protein was highly expressed at about 20% of the total bacterial proteins and was identified by Western blot. After purification with Ni-NTA affinity chromatography and refolding with renaturation buffer, the purity of the target hrIL-11 protein reached 95% and its biology activity was 1 x 10(6) IU/mg, determined by stimulating the proliferation of T1165, which facilitates further researches into effects of IL-11 on platelet proliferation and other function.